+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Chondrosarcoma - Market Insight, Epidemiology and Market Forecast - 2030

  • ID: 5238596
  • Report
  • January 2021
  • Region: Global
  • 132 pages
  • DelveInsight

FEATURED COMPANIES

  • Agios Pharmaceuticals
  • Eli Lilly and Company
  • Forma Therapeutics
  • Inhibrx
  • PharmaMar
This ‘Chondrosarcoma-Market Insights, Epidemiology, and Market Forecast-2030' report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of Chondrosarcoma in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The Chondrosarcoma market report provides analysis regarding current treatment practices, emerging drugs like Ivosidenib and other promising candidates like Trabectedin, Olutasidenib, INBRX-109 and LY3410738. Market share of the individual therapies, and historical, current and forecasted Chondrosarcoma market size from 2017 to 2030, segmented by seven major markets.

The report also covers current Chondrosarcoma treatment practice/algorithm, guidelines, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities. It assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2017-2030

Chondrosarcoma- Disease Understanding and Treatment Algorithm


Overview:


Chondrosarcoma comprises a group of locally aggressive or malignant cartilaginous matrix-producing neoplasms with diverse morphological features and clinical behavior. They predominantly arise in bones derived from endochondral ossification, the most common sarcoma of bone in patients above the age of 20 years. It predominantly affects individuals in the fourth to the sixth decades of life. The most commonly involved sites are the bones of the pelvis followed by the femur, humerus and ribs.

Chondrosarcoma occurrence steadily increases with age, with a peak incidence in the fifth to the seventh decade. Chondrosarcomas can be divided into different subtypes based on morphology, molecular alterations, whether they arise de novo (primary) or from benign precursor lesions (secondary) and by their location within the bone [central (in the medulla) or peripheral (at the surface).

Chondrosarcoma is one of the main types of bone sarcoma that shows a considerable deficiency in response to chemotherapy and radiotherapy. While surgery remains a mainstay of treatment, chemo-and radiotherapy is used in this tumor, high rate of death, especially among children and adolescents, are reported. Due to high resistance to current conventional therapies in chondrosarcoma, there is an urgent requirement to recognize factors causing resistance and discover new strategies for optimal treatment.

Treatment:


The current management of chondrosarcoma depends on the type, the grade and the location of the tumor while the best predictor of clinical behavior being the grading system from I to III. It is a well-established proposition that surgical treatment is the best, and the only, treatment for chondrosarcoma as other treatments, such as radiotherapy and chemotherapy, are rendered unresponsive and refractory. Curettage, radical resection, and amputation are the primary surgical treatment options while these procedures often require considerable judgment and are based on factors, such as the size and site of the lesion and its degree of malignancy.

This chapter covers the details of conventional and current medical therapies available for the treatment of Chondrosarcoma. It also provides Chondrosarcoma treatment guidelines across the United States and Europe.

This Chondrosarcoma market report gives a thorough understanding of the disease by including details such as disease definition, etiology, types, neurobiology, biomarkers and diagnosis. It also provides Chondrosarcoma treatment pattern and treatment guidelines in the US and Europe.

Epidemiology:


The Chondrosarcoma epidemiology chapters provide insights about historical and current Chondrosarcoma patient pool and forecasted trends for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. Chondrosarcoma epidemiology is segmented by the incidence of chondrosarcoma, type-specific cases of chondrosarcoma, type-specific cases of primary chondrosarcoma, and grade-specific cases of chondrosarcoma. Besides, the report includes a thorough analysis of all segments.

According to the publisher's, the total prevalent population of Chondrosarcoma in seven major markets was 2,218 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017-2030).

Among all the seven major markets, total prevalent cases for Chondrosarcoma were highest in the United States, followed by France and the United Kingdom. Spain accounted for the least number of prevalent cases among the 7MM.

Drug Chapters:


This segment encloses the detailed analysis of the drugs in the Chondrosarcoma pipeline. It also helps understand the Chondrosarcoma clinical trial details, expressive pharmacological action, agreements of the included drug, and the latest news and press releases.

Current chemotherapy recommendations include cisplatin and doxorubicin, extrapolated from recommended osteosarcoma and Ewing sarcoma treatment regimens. Other combinations of Gemcitabine, Ifosfamide, Dasatinib, and Pazopanib have also demonstrated positive clinical outcomes. Emerging therapies, like AG-120, Trabectedin, are expected to bring a positive shift to the overall market.

Market Outlook:


The market size of Chondrosarcoma is expected to increase at a significant CAGR during the study period (2017-2030). Among the EU5 countries, France had the largest market size, with USD 0.69 million in 2017, while Spain had the smallest market size of chondrosarcoma, with USD 0.27 million.

Drugs Uptake:


This section focuses on the rate of uptake of the potential drugs in the Chondrosarcoma market or expected to get launched in the market during the study period 2017-2030. The analysis covers Chondrosarcoma market uptake by drugs; patient uptake by therapies; and sale of each drug.

It helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size. All of which will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The dynamics of condrosarcoma market is anticipated to experience a major positive shift in the coming years owing to the expected launch of pipeline therapies.

Chondrosarcoma: Pipeline Development Activities


The report provides insights into different therapeutic candidates and also analyses the key players involved in developing targeted therapeutics.

Pipeline Development Activities:


The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details, and emerging therapies, concerning Chondrosarcoma.

KOL Views


To keep up with current market trends,the publisher takes KOLs and SME's opinion working in Chondrosarcoma domain through primary research to fill the data gaps and validate the secondary research. It will support the clients in assessing potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis


The publisher have performed the competitive and market Intelligence analysis of the Chondrosarcoma Market by using various competitive intelligence tools that include SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. Besides, the inclusion of the analysis entirely depends upon the data availability.

Report Highlights

  • In the coming years, Chondrosarcoma market scenario is expected to experience a positive shift across the 7MM due to a robust pipeline.
  • The in-depth analysis of the pipeline assets across different stages of development (Phase II and Phase III), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Chondrosarcoma Report Insights:

  • Patient Population
  • Therapeutic Approaches
  • Chondrosarcoma Pipeline Analysis
  • Chondrosarcoma Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Chondrosarcoma Report Key Strengths:

  • 11 years Forecast
  • 7MM Coverage
  • Chondrosarcoma Epidemiology Segmentation
  • Key Cross Competition
  • Market Size by Therapies
  • Drugs Uptake

Chondrosarcoma Report Assessment:

  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers

Key Questions Answered


Market Insights:

  • What was the Chondrosarcoma market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Chondrosarcoma total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Chondrosarcoma market size during the forecast period (2017-2030)?
  • At what CAGR, the Chondrosarcoma market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Chondrosarcoma market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Chondrosarcoma market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What are the disease risk, burden and unmet needs of Chondrosarcoma?
  • What is the historical Chondrosarcoma patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Chondrosarcoma in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population pertaining to Chondrosarcoma?
  • Out of all 7MM countries, which country would have the highest prevalent population of Chondrosarcoma during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for Chondrosarcoma treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Chondrosarcoma in the USA, Europe, and Japan?
  • How many companies are developing therapies for the treatment of Chondrosarcoma?
  • How many therapies are developed by each company for Chondrosarcoma?
  • How many are emerging therapies in mid-stage, and late stage of development for Chondrosarcoma treatment?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chondrosarcoma therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Chondrosarcoma and their status?
  • What are the key designations that have been granted for the emerging therapies for Chondrosarcoma?
  • What is the global historical and forecasted market of Chondrosarcoma?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Chondrosarcoma market
  • To understand the future market competition in the Chondrosarcoma market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Chondrosarcoma in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Chondrosarcoma market
  • To understand the future market competition in the Chondrosarcoma market
Which geography accounted for the largest Chondrosarcoma market size?

The United States accounted for the largest Chondrosarcoma market size.

What is forecasted Chondrosarcoma size in 2030?

The publisher estimates an increase in Chondrosarcoma Market Size during the study period, 2017-2030

What are the present Chondrosarcoma market drivers?

Shortcomings associated with existing treatment options, improvement in diagnosis practices, new approaches towards therapy development

What are the Chondrosarcoma market barriers?

The rarity of disease, a better understanding of underlying molecular mechanisms, issues associated with therapy development

How many companies are developing drugs for Chondrosarcoma?

Currently, one key pharma player is developing the drug for Chondrosarcoma

Which are the leading companies in Chondrosarcoma market?

Key Player - Agios Pharmaceuticals

How is epidemiology segmented for Chondrosarcoma?

Incidence of chondrosarcoma, type-specific cases of chondrosarcoma, type-specific cases of primary chondrosarcoma and grade-specific cases of chondrosarcoma
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Agios Pharmaceuticals
  • Eli Lilly and Company
  • Forma Therapeutics
  • Inhibrx
  • PharmaMar
1 Key Insights

2 Executive Summary of Chondrosarcoma

3 SWOT Analysis for Chondrosarcoma

4 Chondrosarcoma Market Overview at a Glance
4.1 Market Share (%) Distribution of Chondrosarcoma In 2017
4.2 Market Share (%) Distribution of Chondrosarcoma In 2030

5 Disease Background and Overview
5.1 Introduction
5.2 Histological grading
5.3 Classification and characteristics of Chondrosarcoma
5.3.1 Conventional chondrosarcoma
5.3.2 Non-conventional chondrosarcoma
5.4 Signaling pathways involved in chondrosarcoma development
5.5 Biomarkers
5.6 Diagnosis

6 Epidemiology and Patient Population
6.1 Key Findings
6.2 7MM Total Incident Patient Population of Chondrosarcoma
6.3 Assumptions and Rationale
6.4 The United States
6.4.1 Incident Population of Chondrosarcoma in the United States
6.4.2 Type-specific cases of Chondrosarcoma in the United States
6.4.3 Type-specific cases of Primary Chondrosarcoma in the United States
6.4.4 Grade-specific cases of Chondrosarcoma in the United States
6.5 EU5 Countries
6.5.1 Germany
6.5.1.1 Incident Population of Chondrosarcoma in Germany
6.5.1.2 Type-specific cases of Chondrosarcoma in Germany
6.5.1.3 Type-specific cases of Primary Chondrosarcoma in Germany
6.5.1.4 Grade-specific cases of Chondrosarcoma in Germany
6.5.2 France
6.5.2.1 Incident Population of Chondrosarcoma in France
6.5.2.2 Type-specific cases of Chondrosarcoma in France
6.5.2.3 Type-specific cases of Primary Chondrosarcoma in France
6.5.2.4 Grade-specific cases of Chondrosarcoma in France
6.5.3 Italy
6.5.3.1 Incident Population of Chondrosarcoma in Italy
6.5.3.2 Type-specific cases of Chondrosarcoma in Italy
6.5.3.3 Type-specific cases of Primary Chondrosarcoma in Italy
6.5.3.4 Grade-specific cases of Chondrosarcoma in Italy
6.5.4 Spain
6.5.4.1 Incident Population of Chondrosarcoma in Spain
6.5.4.2 Type-specific cases of Chondrosarcoma in Spain
6.5.4.3 Type-specific cases of Primary Chondrosarcoma in Spain
6.5.4.4 Grade-specific cases of Chondrosarcoma in Spain
6.5.5 The United Kingdom
6.5.5.1 Incident Population of Chondrosarcoma in the United Kingdom
6.5.5.2 Type-specific cases of Chondrosarcoma in the United Kingdom
6.5.5.3 Type-specific cases of Primary Chondrosarcoma in the United Kingdom
6.5.5.4 Grade-specific cases of Chondrosarcoma in the United Kingdom
6.6 Japan
6.6.1 Incident Population of Chondrosarcoma in Japan
6.6.2 Type-specific cases of Chondrosarcoma in Japan
6.6.3 Type-specific cases of Primary Chondrosarcoma in Japan
6.6.4 Grade-specific cases of Chondrosarcoma in Japan

7 Treatment and Management
7.1 Treatment Guidelines
7.1.1 NCCN Guidelines
7.1.2 ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

8 Case Study
8.1 Intraspinal Mesenchymal Chondrosarcoma: Report of a Pediatric Case and Literature Review

9 Patient Journey

10 Unmet Needs

11 Emerging Therapies
11.1 AG-120: Agios Pharmaceuticals
11.1.1 Product Description
11.1.2 Clinical Development
11.1.2.1 Clinical trials information
11.1.3 Safety and Efficacy

12 Other Promising Candidates
12.1 Trabectedin: PharmaMar
12.1.1 Product Description
12.1.2 Product development activities
12.1.3 Clinical Development
12.1.3.1 Clinical trials information
12.2 Olutasidenib: Forma Therapeutics
12.2.1 Product Description
12.2.2 Clinical Development
12.2.2.1 Clinical trials information
12.3 INBRX-109: Inhibrx
12.3.1 Product Description
12.3.2 Product Development Activities
12.3.3 Safety and Efficacy
12.4 LY3410738: Eli Lilly and Company
12.4.1 Product Description
12.4.2 Clinical Development
12.4.2.1 Clinical trials information

13 Chondrosarcoma: Seven Major Market Analysis
13.1 Key Findings
13.2 Market Size of Chondrosarcoma in 7MM

14 Market Outlook by Country
14.1 Assumption and Rationale
14.2 United States
14.2.1 Total Market size of Chondrosarcoma
14.2.2 US Drug-level Revenue ($M) for Grade-3 CS Cases
14.2.3 US Drug-level Revenue ($M) for Mesenchymal CS cases
14.2.4 US Drug-level Revenue ($M) for Dedifferentiated CS Cases
14.3 EU5 Countries
14.3.1 Germany
14.3.1.1 Total Market size of Chondrosarcoma
14.3.1.2 Germany Drug-level Revenue ($M) for Grade-3 CS Cases
14.3.1.3 Germany Drug-level Revenue ($M) for Mesenchymal CS cases
14.3.1.4 Germany Drug-level Revenue ($M) for Dedifferentiated CS Cases
14.3.2 France
14.3.2.1 Total Market size of Chondrosarcoma
14.3.2.2 France Drug-level Revenue ($M) for Grade-3 CS Cases
14.3.2.3 France Drug-level Revenue ($M) for Mesenchymal CS cases
14.3.2.4 France Drug-level Revenue ($M) for Dedifferentiated CS Cases
14.3.3 Italy
14.3.3.1 Total Market size of Chondrosarcoma
14.3.3.2 Italy Drug-level Revenue ($M) for Grade-3 CS Cases
14.3.3.3 Italy Drug-level Revenue ($M) for Mesenchymal CS cases
14.3.3.4 Italy Drug-level Revenue ($M) for Dedifferentiated CS Cases
14.3.4 Spain
14.3.4.1 Total Market size of Chondrosarcoma in Spain
14.3.4.2 Market Size by Therapies for Grade-3 Metastatic Chondrosarcoma
14.3.4.3 Market Size by Therapies for Mesenchymal Chondrosarcoma
14.3.4.4 Market Size by Therapies for Dedifferentiated Chondrosarcoma
14.3.5 UK
14.3.5.1 Total Market size of Chondrosarcoma in the UK
14.3.5.2 Market Size by Therapies for Grade-3 Metastatic Chondrosarcoma
14.3.5.3 Market Size by Therapies for Mesenchymal Chondrosarcoma
14.3.5.4 Market Size by Therapies for Dedifferentiated Chondrosarcoma

15 Japan
15.1 Total Market size of Chondrosarcoma in Japan
15.2 Market Size by Therapies for Grade-3 Metastatic Chondrosarcoma
15.3 Market Size by Therapies for Mesenchymal Chondrosarcoma
15.4 Market Size by Therapies for Dedifferentiated Chondrosarcoma

16 Market Drivers

17 Market Barriers

18 Appendix
18.1 Report Methodology

19 Publisher Capabilities

20 Disclaimer

21 About the Publisher

List of Tables
Table 1: Summary of Chondrosarcoma Market, Epidemiology, and Key Events (2017-2030)
Table 2:Total Incident Patient Population of Chondrosarcoma in the 7MM (2017-2030)
Table 3: Incident Population of Chondrosarcoma in the United States (2017-2030)
Table 4: Type-specific cases of Chondrosarcoma in the United States (2017-2030)
Table 5: Type-specific cases of Primary Chondrosarcoma in the United States (2017-2030)
Table 6: Grade-specific cases of Chondrosarcoma in the United States (2017-2030)
Table 7: Incident Population of Chondrosarcoma in Germany (2017-2030)
Table 8: Type-specific cases of Chondrosarcoma in Germany (2017-2030)
Table 9: Type-specific cases of Primary Chondrosarcoma in Germany (2017-2030)
Table 10: Grade-specific cases of Chondrosarcoma in Germany (2017-2030)
Table 11: Incident Population of Chondrosarcoma in France (2017-2030)
Table 12: Type-specific cases of Chondrosarcoma in France (2017-2030)
Table 13: Type-specific cases of Primary Chondrosarcoma in France (2017-2030)
Table 14: Grade-specific cases of Chondrosarcoma in France (2017-2030)
Table 15: Incident Population of Chondrosarcoma in Italy (2017-2030)
Table 16: Type-specific cases of Chondrosarcoma in Italy (2017-2030)
Table 17: Type-specific cases of Primary Chondrosarcoma in Italy (2017-2030)
Table 18: Grade-specific cases of Chondrosarcoma in Italy (2017-2030)
Table 19: Incident Population of Chondrosarcoma in Spain (2017-2030)
Table 20: Type-specific cases of Chondrosarcoma in Spain (2017-2030)
Table 21: Type-specific cases of Primary Chondrosarcoma in Spain (2017-2030)
Table 22: Grade-specific cases of Chondrosarcoma in Spain (2017-2030)
Table 23: Incident Population of Chondrosarcoma in the United Kingdom (2017-2030)
Table 24: Type-specific cases of Chondrosarcoma in the United Kingdom (2017-2030)
Table 25: Type-specific cases of Primary Chondrosarcoma in the United Kingdom (2017-2030)
Table 26: Grade-specific cases of Chondrosarcoma in the United Kingdom (2017-2030)
Table 27: Incident Population of Chondrosarcoma in Japan (2017-2030)
Table 28: Type-specific cases of Chondrosarcoma in Japan (2017-2030)
Table 29: Type-specific cases of Primary Chondrosarcoma in Japan (2017-2030)
Table 30: Grade-specific cases of Chondrosarcoma in Japan (2017-2030)
Table 31: AG-120, Clinical Trial Description, 2020
Table 32: Trabectedin, Clinical Trial Description, 2020
Table 33: Olutasidenib, Clinical Trial Description, 2020
Table 34: LY3410738, Clinical Trial Description, 2020
Table 35: Seven Major Market Size of Chondrosarcoma in USD Million (2017-2030)
Table 36: The US Market size of Chondrosarcoma in USD Million (2017-2030)
Table 37: US Drug-level Revenue ($M) for Grade-3 CS Cases (2017-2030)
Table 38: US Drug-level Revenue ($M) for Mesenchymal CS cases (2017-2030)
Table 39: US Drug-level Revenue ($M) for Dedifferentiated CS Cases (2017-2030)
Table 40: Germany Market size of Chondrosarcoma in Germany USD Million (2017-2030)
Table 41: Germany Drug-level Revenue ($M) for Grade-3 CS Cases (2017-2030)
Table 42: Germany Drug-level Revenue ($M) for Mesenchymal CS cases (2017-2030)
Table 43: Germany Drug-level Revenue ($M) for Dedifferentiated CS Cases (2017-2030)
Table 44: France Market size of Chondrosarcoma in France USD Million (2017-2030)
Table 45: France Drug-level Revenue ($M) for Grade-3 CS Cases (2017-2030)
Table 46: France Drug-level Revenue ($M) for Mesenchymal CS cases (2017-2030)
Table 47: France Drug-level Revenue ($M) for Dedifferentiated CS Cases (2017-2030)
Table 48: Italy Market size of Chondrosarcoma in Italy USD Million (2017-2030)
Table 49: Italy Drug-level Revenue ($M) for Grade-3 CS Cases (2017-2030)
Table 50: Italy Drug-level Revenue ($M) for Mesenchymal CS cases (2017-2030)
Table 51: Italy Drug-level Revenue ($M) for Dedifferentiated CS Cases (2017-2030)
Table 52: Spain Market size of Chondrosarcoma in USD Million (2017-2030)
Table 53: Spain market size by therapies of Grade-3 Metastatic Chondrosarcoma in USD Million (2017-2030)
Table 54: Spain market size by therapies of Mesenchymal Chondrosarcoma in USD Million (2017-2030)
Table 55: Spain market size by therapies of Dedifferentiated Chondrosarcoma in USD Million (2017-2030)
Table 56: UK Market size of Chondrosarcoma in USD Million (2017-2030)
Table 57: UK market size by therapies of Grade-3 Metastatic Chondrosarcoma in USD Million (2017-2030)
Table 58: UK market size by therapies of Mesenchymal Chondrosarcoma in USD Million (2017-2030)
Table 59: UK market size by therapies of Dedifferentiated Chondrosarcoma in USD Million (2017-2030)
Table 60: Japan Market size of Chondrosarcoma in USD Million (2017-2030)
Table 61: Japan market size by therapies of Grade-3 Metastatic Chondrosarcoma in USD Million (2017-2030)
Table 62: Japan market size by therapies of Mesenchymal Chondrosarcoma in USD Million (2017-2030)
Table 63: Japan market size by therapies of Dedifferentiated Chondrosarcoma in USD Million (2017-2030)

List of Figures
Figure 1: SWOT Analysis
Figure 2: The involved molecular pathways responsible for CH development
Figure 3: Chondrosarcoma signaling
Figure 4: The IHH/PTHrP signaling pathway
Figure 5: Incident Cases of Chondrosarcoma in the 7MM (2017-2030)
Figure 6: Incident Population of Chondrosarcoma in the United States (2017-2030)
Figure 7: Type-specific cases of Chondrosarcoma in the United States (2017-2030)
Figure 8: Type-specific cases of Primary Chondrosarcoma in the United States (2017-2030)
Figure 9: Grade-specific cases of Chondrosarcoma in the United States (2017-2030)
Figure 10: Incident Population of Chondrosarcoma in Germany (2017-2030)
Figure 11: Type-specific cases of Chondrosarcoma in Germany (2017-2030)
Figure 12: Type-specific cases of Primary Chondrosarcoma in Germany (2017-2030)
Figure 13: Grade-specific cases of Chondrosarcoma in Germany (2017-2030)
Figure 14: Incident Population of Chondrosarcoma in France (2017-2030)
Figure 15: Type-specific cases of Chondrosarcoma in France (2017-2030)
Figure 16: Type-specific cases of Primary Chondrosarcoma in France (2017-2030)
Figure 17: Grade-specific cases of Chondrosarcoma in France (2017-2030)
Figure 18: Incident Population of Chondrosarcoma in Italy (2017-2030)
Figure 19: Type-specific cases of Chondrosarcoma in Italy (2017-2030)
Figure 20: Type-specific cases of Primary Chondrosarcoma in Italy (2017-2030)
Figure 21: Grade-specific cases of Chondrosarcoma in Italy (2017-2030)
Figure 22: Incident Population of Chondrosarcoma in Spain (2017-2030)
Figure 23: Type-specific cases of Chondrosarcoma in Spain (2017-2030)
Figure 24: Type-specific cases of Primary Chondrosarcoma in Spain (2017-2030)
Figure 25: Grade-specific cases of Chondrosarcoma in Spain (2017-2030)
Figure 26: Incident Population of Chondrosarcoma in the United Kingdom (2017-2030)
Figure 27: Type-specific cases of Chondrosarcoma in the United Kingdom (2017-2030)
Figure 28: Type-specific cases of Primary Chondrosarcoma in the United Kingdom (2017-2030)
Figure 29: Grade-specific cases of Chondrosarcoma in the United Kingdom (2017-2030)
Figure 30: Incident Population of Chondrosarcoma in Japan (2017-2030)
Figure 31: Type-specific cases of Chondrosarcoma in Japan (2017-2030)
Figure 32: Type-specific cases of Primary Chondrosarcoma in Japan (2017-2030)
Figure 33: Grade-specific cases of Chondrosarcoma in Japan (2017-2030)
Figure 34: Low grade and intracompartmental (CHON-2)
Figure 35: High grade or clear cell or extracompartmental (CHON-3)
Figure 36: Metastatic chondrosarcoma (CHON-4)
Figure 37: Dedifferentiated Chondrosarcoma
Figure 38: Surveillance (OSTEO-4)
Figure 39: (OSTEO-2)
Figure 40: (OSTEO-3)
Figure 41: Treatment of Mesenchymal Chondrosarcoma
Figure 42: Patient Journey
Figure 43: Unmet Needs for chondrosarcoma
Figure 44: Seven Major Market Size of Chondrosarcoma in USD Million (2017-2030)
Figure 45: Market Size of Chondrosarcoma in the United States, USD Millions (2017-2030)
Figure 46: US Drug-level Revenue ($M) for Grade-3 CS Cases (2017-2030)
Figure 47: US Drug-level Revenue ($M) for Mesenchymal CS cases (2017-2030)
Figure 48: US Drug-level Revenue ($M) for Dedifferentiated CS Cases (2017-2030)
Figure 49: Market Size of CHONDROSARCOMA in Germany, Germany USD Millions (2017-2030)
Figure 50: Germany Drug-level Revenue ($M) for Grade-3 CS Cases (2017-2030)
Figure 51: Germany Drug-level Revenue ($M) for Mesenchymal CS cases (2017-2030)
Figure 52: Germany Drug-level Revenue ($M) for Dedifferentiated CS Cases (2017-2030)
Figure 53: Market Size of CHONDROSARCOMA in France, France USD Millions (2017-2030)
Figure 54: France Drug-level Revenue ($M) for Grade-3 CS Cases (2017-2030)
Figure 55: France Drug-level Revenue ($M) for Mesenchymal CS cases (2017-2030)
Figure 56: France Drug-level Revenue ($M) for Dedifferentiated CS Cases (2017-2030)
Figure 57: Market Size of CHONDROSARCOMA in Italy, Italy USD Millions (2017-2030)
Figure 58: Italy Drug-level Revenue ($M) for Grade-3 CS Cases (2017-2030)
Figure 59: Italy Drug-level Revenue ($M) for Mesenchymal CS cases (2017-2030)
Figure 60: Italy Drug-level Revenue ($M) for Dedifferentiated CS Cases (2017-2030)
Figure 61: Market Size of Chondrosarcoma in Spain, USD Millions (2017-2030)
Figure 62: Spain market size by therapies of Grade-3 Metastatic Chondrosarcoma in USD Million (2017-2030)
Figure 63: Spain market size by therapies of Mesenchymal Chondrosarcoma in USD Million (2017-2030)
Figure 64: Spain market size by therapies of Dedifferentiated Chondrosarcoma in USD Million (2017-2030)
Figure 65: Market Size of Chondrosarcoma in the UK, USD Millions (2017-2030)
Figure 66: UK market size by therapies of Grade-3 Metastatic Chondrosarcoma in USD Million (2017-2030)
Figure 67: UK market size by therapies of Mesenchymal Chondrosarcoma in USD Million (2017-2030)
Figure 68: UK market size by therapies of Dedifferentiated Chondrosarcoma in USD Million (2017-2030)
Figure 69: Market Size of Chondrosarcoma in Japan, USD Millions (2017-2030)
Figure 70: Japan market size by therapies of Grade-3 Metastatic Chondrosarcoma in USD Million (2017-2030)
Figure 71: Japan market size by therapies of Mesenchymal Chondrosarcoma in USD Million (2017-2030)
Figure 72: Japan market size by therapies of Dedifferentiated Chondrosarcoma in USD Million (2017-2030)
Figure 73: Market drivers for Chondrosarcoma
Figure 74:Market Barriers for Chondrosarcoma
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Agios Pharmaceuticals
  • PharmaMar
  • Forma Therapeutics
  • Inhibrx
  • Eli Lilly and Company
Note: Product cover images may vary from those shown
Adroll
adroll